Q&A with Taofeek Owonikoko, MD, PhD

Tagged with:

In honor of Lung Cancer Awareness month this November, this research highlight focuses on Taofeek K. Owonikoko, MD, PhD. Dr. Owonikoko is Chief of the Division of Hematology/Oncology, Associate Director for Translational Research, and Co-Leader of the Cancer Therapeutics Program

Research Spotlight: Dr. Steffi Oesterreich

Tagged with:

Steffi Oesterreich, PhD, is a researcher at UPMC Hillman Cancer Center who focuses her work on better understanding how to most effectively treat breast cancers, including invasive lobular carcinoma (ILC) and estrogen receptor-positive (ESR1) breast cancer resistant to hormonal therapies. 

New postdoctoral training program at Hillman

We at UPMC Hillman Cancer Center are pleased to announce a new and exciting postdoctoral training opportunity. Made possible by a generous donation from Henry L. Hillman Foundation, the Hillman Postdoctoral Fellows for Innovative Cancer Research program seeks the nation’s

Hillman Researcher shows that the proapoptotic protein PUMA also enhances necroptosis

Multiple classes of chemotherapeutic drugs work by inducing cancer cell death, but these drugs are often ineffective in treating cancer patients. Dr. Lin Zhang, Professor of Pharmacology and Chemical Biology, seeks to improve treatment outcome by studying the mechanisms underlying

Clinical Trials at UPMC Hillman Cancer Center

Basic and translational researchers at UPMC Hillman Cancer Center work closely with physician-scientists and clinicians to quickly move the most promising research results from their labs into clinical trials. While the conduct of clinical studies provides critical information to researchers

Pitt and UPMC Launch New Immune Transplant and Therapy Center (ITTC)

On February 13, Pitt and UPMC leaders announced plans to establish the new UPMC Immune Transplant and Therapy Center (ITTC), with much of its activity planned within an eight-story innovation hub—all part of a concerted effort to harness the power

Hillman Researcher Aims to Target Colorectal Cancer with a Multifaceted Approach

Colorectal cancer (CRC) is a leading cause of cancer death in the United States and worldwide. While common oncogenic mutations in CRC have been identified, attempts to target these pathways have had limited success. Jian Yu, PhD, Professor of Pathology

Ovarian Cancer Cells Manipulate Surrounding Normal Cells to Aid Tumor Growth

Tumors do not grow in isolation, but are surrounded by a rich microenvironment that contains blood vessels, fibroblasts, immune cells, and a multitude of other components. Cancer cells can influence their microenvironment through extracellular signaling mechanisms to enable and/or enhance

Multispectral Tumor Imaging May Guide Precision Immunotherapy

While novel immunotherapies are revolutionizing the way some cancers are treated, not all patients will respond to treatment, underlining the need for biomarkers that can predict potential clinical benefit and monitor a patient’s response. Until recently, immune activity within and

Combination Targeted Therapy Improves Survival of Stage III Melanoma Patients

It is estimated that 40% of melanomas contain BRAF mutations that promote cancer cell growth. While previous studies have shown that treatment with the combination of inhibitors targeting BRAF (dabrafenib) and MEK (trametinib) improved survival in patients with advanced, unresectable

Top